Migraine occurs due to vasodilation of enzyme named calcitonin gene-related peptide (CGRP), and it binds to the receptors causing vasodilation. VYEPTI is a new intravenous drug for migraine and can be used as a preventive treatment. It is a monoclonal antibody that blocks CGRP binding to the receptor, and hence stopping vasodilation. Individuals with migraine will have to take this injection once in 3 months.
Ramasamy B, Karri M, Venkat S, Andhuvan G. Clinical profile and triggers of migraine. Int J Res Med Sci 2019;7(4):1050–1054. DOI: 10.18203/2320-6012.ijrms20191083.
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(Suppl 7): 1–96.
Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000;55(5):629–635. DOI: 10.1212/WNL.55.5.629.
Jayalakshmi S, Vooturi S. Migraine and mood disorders: prevalence, clinical correlations, and disability. J Neurosci Rural Pract 2019;10(1): 1–2. DOI: 10.4103/jnrp.jnrp_323_18.
Diener H-C, Kurth T. Migraine and stroke. In: Grotta JC, Albers GW, Broderick JP, et al. Stroke: Pathophysiology, Diagnosis, and Management. 6th ed., ch. 43, Philadelphia, PA: Elsevier; 2016.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015;55(1): 3–20. DOI: 10.1111/head.12499.